用于非酒精性脂肪性肝病药物治疗的抗糖尿病药物
Anti-Diabetic Medications for the Pharmacologic Management of NAFLD.
作者信息
Cholankeril Rosann, Patel Vikram, Perumpail Brandon J, Yoo Eric R, Iqbal Umair, Sallam Sandy, Shah Neha D, Kwong Waiyee, Kim Donghee, Ahmed Aijaz
机构信息
Department of Medicine, Roger Williams Medical Center, Providence, RI 02908, USA.
Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, USA.
出版信息
Diseases. 2018 Oct 3;6(4):93. doi: 10.3390/diseases6040093.
Abstract
As a chronic disease encompassing a wide spectrum of liver-related histologic damage, nonalcoholic fatty liver disease (NAFLD) is becoming a global epidemic with significant impacts on all-cause morbidity and mortality. Insulin resistance and type 2 diabetes mellitus predispose individuals to NAFLD and related complications. Therefore, timely intervention with anti-diabetic medications may prevent and delay the development of NAFLD or have a therapeutic implication. The focus of this review is to evaluate the evidence supporting the efficacy of anti-diabetic medications in the treatment of NAFLD. While many of these anti-diabetic agents have shown to improve biochemical parameters, their effect on hepatic histology is limited. Among anti-diabetic medications, only thiazolidinediones and glucagon-like peptide-1 receptor agonists demonstrate significant improvement in hepatic histology.
摘要
非酒精性脂肪性肝病（NAFLD）作为一种涵盖广泛肝脏相关组织学损伤的慢性疾病，正成为一种全球性流行病，对全因发病率和死亡率产生重大影响。胰岛素抵抗和2型糖尿病使个体易患NAFLD及相关并发症。因此，及时使用抗糖尿病药物进行干预可能预防和延缓NAFLD的发展或具有治疗意义。本综述的重点是评估支持抗糖尿病药物治疗NAFLD疗效的证据。虽然这些抗糖尿病药物中的许多已显示可改善生化指标，但其对肝脏组织学的影响有限。在抗糖尿病药物中，只有噻唑烷二酮类和胰高血糖素样肽-1受体激动剂可使肝脏组织学有显著改善。
相似文献
1
Anti-Diabetic Medications for the Pharmacologic Management of NAFLD.
Diseases. 2018 Oct 3;6(4):93. doi: 10.3390/diseases6040093.
2
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Metabolism. 2019 Dec;101:154001. doi: 10.1016/j.metabol.2019.154001. Epub 2019 Oct 28.
3
Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies.
Diabetes Metab Res Rev. 2016 Feb;32(2):200-16. doi: 10.1002/dmrr.2713. Epub 2015 Nov 1.
4
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Curr Diab Rep. 2020 Oct 5;20(11):59. doi: 10.1007/s11892-020-01349-1.
5
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
Diabetes Metab. 2020 Nov;46(6):427-441. doi: 10.1016/j.diabet.2019.12.007. Epub 2020 Jan 7.
6
Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety.
Ther Adv Endocrinol Metab. 2018 Jan;9(1):15-28. doi: 10.1177/2042018817741852. Epub 2017 Dec 7.
7
Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis.
Clin Mol Hepatol. 2023 Jul;29(3):693-704. doi: 10.3350/cmh.2022.0330. Epub 2023 Mar 9.
8
Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
J Clin Exp Hepatol. 2012 Jun;2(2):156-73. doi: 10.1016/S0973-6883(12)60104-2. Epub 2012 Jul 21.
9
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Diabetologia. 2016 Jun;59(6):1112-20. doi: 10.1007/s00125-016-3952-1. Epub 2016 Apr 21.
10
Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus.
Hepatol Res. 2017 Mar;47(4):266-280. doi: 10.1111/hepr.12856. Epub 2017 Feb 13.
引用本文的文献
1
Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis.
World J Gastrointest Pharmacol Ther. 2024 Nov 5;15(6):97381. doi: 10.4292/wjgpt.v15.i6.97381.
2
Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system: a review.
Arch Toxicol. 2025 Jan;99(1):1-22. doi: 10.1007/s00204-024-03889-x. Epub 2024 Oct 23.
3
Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.
Obes Pillars. 2022 Jul 8;3:100027. doi: 10.1016/j.obpill.2022.100027. eCollection 2022 Sep.
4
Hunger & satiety signals: another key mechanism involved in the NAFLD pathway.
Front Endocrinol (Lausanne). 2023 Sep 11;14:1213372. doi: 10.3389/fendo.2023.1213372. eCollection 2023.
5
Advances in Unhealthy Nutrition and Circadian Dysregulation in Pathophysiology of NAFLD.
Front Clin Diabetes Healthc. 2021 Oct 12;2:691828. doi: 10.3389/fcdhc.2021.691828. eCollection 2021.
6
Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation.
Sci Rep. 2021 Jun 23;11(1):13159. doi: 10.1038/s41598-021-92264-2.
7
Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment.
Front Med (Lausanne). 2021 Apr 14;8:615978. doi: 10.3389/fmed.2021.615978. eCollection 2021.
8
Combination of bis (α-furancarboxylato) oxovanadium (IV) and metformin improves hepatic steatosis through down-regulating inflammatory pathways in high-fat diet-induced obese C57BL/6J mice.
Basic Clin Pharmacol Toxicol. 2021 Jun;128(6):747-757. doi: 10.1111/bcpt.13573. Epub 2021 Mar 14.
9
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease.
Clin Mol Hepatol. 2021 Apr;27(2):221-235. doi: 10.3350/cmh.2020.0239. Epub 2020 Dec 3.
10
S-allylmercaptocysteine improves nonalcoholic steatohepatitis by enhancing AHR/NRF2-mediated drug metabolising enzymes and reducing NF-κB/IκBα and NLRP3/6-mediated inflammation.
Eur J Nutr. 2021 Mar;60(2):961-973. doi: 10.1007/s00394-020-02305-1. Epub 2020 Jun 17.
本文引用的文献
1
The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD).
Hormones (Athens). 2018 Jun;17(2):219-229. doi: 10.1007/s42000-018-0021-9. Epub 2018 Apr 17.
2
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis.
Diabetes Care. 2018 Feb;41(2):372-382. doi: 10.2337/dc17-1902.
3
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
JAMA Intern Med. 2017 May 1;177(5):633-640. doi: 10.1001/jamainternmed.2016.9607.
4
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.
World J Gastroenterol. 2017 Jan 7;23(1):141-150. doi: 10.3748/wjg.v23.i1.141.
5
Therapies in non-alcoholic steatohepatitis (NASH).
Liver Int. 2017 Jan;37 Suppl 1(Suppl 1):97-103. doi: 10.1111/liv.13302.
6
Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects.
Endocr J. 2017 Mar 31;64(3):363-367. doi: 10.1507/endocrj.EJ16-0295. Epub 2016 Dec 13.
7
Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.
Hepatol Res. 2017 Sep;47(10):1072-1078. doi: 10.1111/hepr.12834. Epub 2016 Dec 7.
8
Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.
Hepatol Res. 2017 Oct;47(11):1206-1211. doi: 10.1111/hepr.12837. Epub 2016 Dec 5.
9
The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background.
Gastroenterol Res Pract. 2016;2016:2862173. doi: 10.1155/2016/2862173. Epub 2016 May 9.
10
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
J Hepatol. 2016 Aug;65(2):369-76. doi: 10.1016/j.jhep.2016.04.021. Epub 2016 May 2.
Zotero 插件